PULMONARY ARTERIAL HYPERTENSION
Clinical trials for PULMONARY ARTERIAL HYPERTENSION explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to help lungs and heart work better during exercise
Disease control TerminatedThis phase 3 trial tests whether ralinepag, an oral medication, can improve exercise capacity in people with pulmonary arterial hypertension (PAH) who have recently started PAH therapy. Participants take ralinepag or a placebo for 28 weeks, and their peak oxygen consumption durin…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New biologic KER-012 shows promise for Hard-to-Treat lung condition
Disease control TerminatedThis phase 2 trial tested an experimental biologic called KER-012 in 113 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants received either KER-012 or a placebo as a shot every 4 weeks, on top of their usual PAH…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug sotatercept tested to slow PAH progression
Disease control TerminatedThis Phase 3 trial tested the drug sotatercept in 321 people newly diagnosed with intermediate- or high-risk pulmonary arterial hypertension (PAH). Participants received either sotatercept or a placebo added to their usual PAH therapy. The goal was to see if sotatercept could del…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
PAH drug LTP001 safety study ends early – limited data available
Disease control TerminatedThis study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental PAH drug trial halted early
Disease control TerminatedThis study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial w…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC